Fitting a spherical acrylic intraocular lens (IOL) in patients with bilateral cataract improves corrected distance visual acuity (CDVA) more so than fitting an aspheric IOL.
Fitting a spherical acrylic intraocular lens (IOL) in patients with bilateral cataract improves corrected distance visual acuity (CDVA) more so than fitting an aspheric IOL, claims an investigation featured in Journal of Cataract and Refractive Surgery.
Dr Manickam Thiagarajan and his team, Eye Department, Southampton University Hospital, UK, conducted a randomized, masked, single-centre study on bilateral cataract patients aged 50 years and over. The biometry-predicted IOL power was between 10.0 D and 30.0 D. Patients were fitted with the Akreos Adapt Advanced Optics aspheric IOL and the Sensar AR40e spherical acrylic IOL.
A high-contrast logMAR chart was used to measure CDVA, the Pelli-Robson chart was used to measure contrast sensitivity, range of accommodation was measured using the RAF rule and patient satisfaction was recorded by questionnaire 3 months postoperatively. Pseudoaccommodation, mesopic pupil diameters and scotopic pupil diameters were all measured with a power refractor.
The difference in mean CDVA between the IOLs was 0.015, with the spherical IOL scoring the highest. The differences between contrast sensitivity and range of accommodation were 0.02 and 0.05, respectively. The questionnaire answers produced no differences in dysphotopsia and patient satisfaction.
The spherical IOL demonstrated a statistically significant improvement in CDVA but the findings are not clinically important.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.